MIRA Pharmaceuticals Publishes Peer-Reviewed Manuscript on SKNY-1 Preclinical Data

MIRA PHARMACEUTICALS, INC.

Manuscript titled 'SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors' published in International Journal of Molecular Sciences.
SKNY-1 oral administration produced approximately 30% reduction in body weight from baseline after six days in the higher-dose group.
SKNY-1 demonstrated differential CB1 signaling, partial CB2 agonist activity, and selective MAO-B inhibition relative to MAO-A.
Preclinical findings included normalization of total cholesterol and LDL, increased HDL, reduced hepatic triglycerides, and attenuated compulsive feeding and nicotine-seeking behaviors.
SKNY-1 has not been approved by the FDA; safety and efficacy not yet established in humans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.